4888 — Stella Pharma Balance Sheet
0.000.00%
Last trade - 00:00- ¥14bn
- ¥11bn
- ¥961m
Annual balance sheet for Stella Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,251 | 3,276 | 2,710 | 2,354 | 3,206 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 55.1 | 16.9 | 59.3 | 76.2 | 715 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,811 | 4,175 | 3,793 | 3,629 | 5,243 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 68.5 | 92 | 103 | 81.5 | 66.5 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,049 | 4,719 | 4,329 | 3,821 | 5,417 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 319 | 308 | 422 | 456 | 390 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 1,818 | 1,639 | 1,577 | 1,444 | 2,210 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 231 | 3,080 | 2,753 | 2,377 | 3,207 |
| Total Liabilities & Shareholders' Equity | 2,049 | 4,719 | 4,329 | 3,821 | 5,417 |
| Total Common Shares Outstanding |